- Home
- OPTN vs HBIO Comparison
OPTN vs HBIO Comparison
Compare OPTN & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPTN
- HBIO
- Stock Information
- Founded
- OPTN 2010
- HBIO 1901
- Country
- OPTN United States
- HBIO United States
- Employees
- OPTN N/A
- HBIO N/A
- Industry
- OPTN Biotechnology: Pharmaceutical Preparations
- HBIO Biotechnology: Laboratory Analytical Instruments
- Sector
- OPTN Health Care
- HBIO Industrials
- Exchange
- OPTN Nasdaq
- HBIO Nasdaq
- Market Cap
- OPTN 99.7M
- HBIO 106.4M
- IPO Year
- OPTN 2017
- HBIO 2000
- Fundamental
- Price
- OPTN $0.46
- HBIO $2.25
- Analyst Decision
- OPTN Strong Buy
- HBIO
- Analyst Count
- OPTN 3
- HBIO 0
- Target Price
- OPTN $3.00
- HBIO N/A
- AVG Volume (30 Days)
- OPTN 617.5K
- HBIO 133.8K
- Earning Date
- OPTN 11-12-2024
- HBIO 11-07-2024
- Dividend Yield
- OPTN N/A
- HBIO N/A
- EPS Growth
- OPTN N/A
- HBIO N/A
- EPS
- OPTN N/A
- HBIO N/A
- Revenue
- OPTN $75,672,000.00
- HBIO $97,732,000.00
- Revenue This Year
- OPTN $24.44
- HBIO N/A
- Revenue Next Year
- OPTN $49.00
- HBIO N/A
- P/E Ratio
- OPTN N/A
- HBIO N/A
- Revenue Growth
- OPTN 5.13
- HBIO N/A
- 52 Week Low
- OPTN $0.44
- HBIO $2.15
- 52 Week High
- OPTN $2.10
- HBIO $5.56
- Technical
- Relative Strength Index (RSI)
- OPTN 28.38
- HBIO 41.36
- Support Level
- OPTN $0.50
- HBIO $2.30
- Resistance Level
- OPTN $0.81
- HBIO $2.61
- Average True Range (ATR)
- OPTN 0.06
- HBIO 0.14
- MACD
- OPTN -0.02
- HBIO -0.02
- Stochastic Oscillator
- OPTN 3.23
- HBIO 5.97
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
About HBIO Harvard Bioscience Inc.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.